Published in Haemostasis on November 09, 2000
Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood (2005) 3.71
How I treat paroxysmal nocturnal hemoglobinuria. Blood (2009) 1.97
The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab. Ther Clin Risk Manag (2009) 1.16
Thrombolytic therapy is effective in paroxysmal nocturnal hemoglobinuria: a series of nine patients and a review of the literature. Haematologica (2011) 0.87
Paroxysmal nocturnal hemoglobinuria and pregnancy before the eculizumab era: the French experience. Haematologica (2011) 0.85
Multidisciplinary clinical management of paroxysmal nocturnal hemoglobinuria. Am J Blood Res (2015) 0.85
Paroxysmal nocturnal hemoglobinuria presenting as cerebral venous sinus thrombosis: a case report. Int Arch Med (2014) 0.82
Clinical management of paroxysmal nocturnal haemoglobinuria in pregnancy: three case reports. Blood Transfus (2010) 0.81
The complement system and adverse pregnancy outcomes. Mol Immunol (2015) 0.80
Successful pregnancy outcome in paroxysmal nocturnal hemoglobinuria (PNH) following escalated eculizumab dosing to control breakthrough hemolysis. Leuk Res Rep (2015) 0.79
Increased eculizumab requirements during pregnancy in a patient with paroxysmal nocturnal hemoglobinuria: case report and review of the literature. Clin Case Rep (2014) 0.79
Paroxysmal nocturnal hemoglobinuria in a girl with hemolysis and "hematuria". Pediatr Nephrol (2004) 0.77
Management of thrombosis in paroxysmal nocturnal hemoglobinuria: a clinician's guide. Ther Adv Hematol (2016) 0.75
Eculizumab in the management of paroxysmal nocturnal hemoglobinuria: patient selection and special considerations. Ther Clin Risk Manag (2016) 0.75
Complement Activation in Placental Malaria. Front Microbiol (2015) 0.75
Ischemic Stroke Presenting as the First Symptom in a Setting of Paroxysmal Nocturnal Hemoglobinuria. Cureus (2017) 0.75
A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med (1999) 5.14
Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost (2000) 4.81
Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet (2000) 2.74
Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med (1990) 2.63
Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia. Blood (1991) 2.54
Use of a clinical model for safe management of patients with suspected pulmonary embolism. Ann Intern Med (1998) 2.49
Establishing a therapeutic range for heparin therapy. Ann Intern Med (1993) 2.31
Thrombosis in antithrombin-III-deficient persons. Report of a large kindred and literature review. Ann Intern Med (1992) 2.23
Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med (2000) 2.12
Real-world variability in dabigatran levels in patients with atrial fibrillation. J Thromb Haemost (2015) 2.07
Noninvasive diagnosis of deep venous thrombosis. McMaster Diagnostic Imaging Practice Guidelines Initiative. Ann Intern Med (1998) 2.03
Graduated compression stockings to treat acute leg pain associated with proximal DVT. A randomised controlled trial. Thromb Haemost (2014) 2.02
Use of prescription drugs in the first trimester and congenital malformations. Aust N Z J Obstet Gynaecol (1991) 1.99
Management of suspected deep venous thrombosis in outpatients by using clinical assessment and D-dimer testing. Ann Intern Med (2001) 1.93
Does this patient have deep vein thrombosis? JAMA (1998) 1.90
The prognosis for live birth among untreated infertile couples. Fertil Steril (1995) 1.76
A simple clinical model for the diagnosis of deep-vein thrombosis combined with impedance plethysmography: potential for an improvement in the diagnostic process. J Intern Med (1998) 1.76
A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med (2000) 1.70
Does the location of thrombosis determine the risk of disease recurrence in patients with proximal deep vein thrombosis? Am J Med (2001) 1.70
Deep vein thrombosis and its prevention in critically ill adults. Arch Intern Med (2001) 1.68
Determinants of health-related quality of life during the 2 years following deep vein thrombosis. J Thromb Haemost (2008) 1.67
Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA (1998) 1.67
A review of upper extremity deep vein thrombosis in pregnancy: unmasking the 'ART' behind the clot. J Thromb Haemost (2006) 1.59
The role of venous ultrasonography in the diagnosis of suspected deep venous thrombosis and pulmonary embolism. Ann Intern Med (1998) 1.58
Fibrinolytic variables in patients with recurrent venous thrombosis: a prospective cohort study. Thromb Haemost (2001) 1.58
The feasibility of a control population for a randomized control trial of seizure prophylaxis in the hypertensive disorders of pregnancy. Am J Obstet Gynecol (1995) 1.47
Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med (1996) 1.45
Subcutaneous heparin therapy during pregnancy: a need for concern at the time of delivery. Thromb Haemost (1991) 1.45
Platelet count may predict abnormal bleeding time among pregnant women with hypertension and preeclampsia. Can J Anaesth (2001) 1.40
Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost (1999) 1.31
Comparison of hysterosalpingography and laparoscopy in predicting fertility outcome. Hum Reprod (1999) 1.30
Venous thromboembolism in patients undergoing rehabilitation for stroke. Arch Phys Med Rehabil (1992) 1.26
Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med (1992) 1.24
Improving question formulation for use in evidence appraisal in a tertiary care setting: a randomised controlled trial [ISRCTN66375463]. BMC Med Inform Decis Mak (2001) 1.24
Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Arch Intern Med (2000) 1.24
Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. J Thromb Haemost (2004) 1.14
A noninvasive strategy for the treatment of patients with suspected pulmonary embolism. Arch Intern Med (1994) 1.08
Predictors of the post-thrombotic syndrome during long-term treatment of proximal deep vein thrombosis. J Thromb Haemost (2005) 1.06
Incidence of venographically proved deep vein thrombosis after knee arthroscopy. Arch Intern Med (1998) 1.06
Economic burden and cost determinants of deep vein thrombosis during 2 years following diagnosis: a prospective evaluation. J Thromb Haemost (2011) 1.06
Tetracycline sclerosis in the management of malignant pericardial effusion. J Clin Oncol (1985) 1.04
The relationship of antiphospholipid antibodies to cognitive function in patients with systemic lupus erythematosus. J Int Neuropsychol Soc (1997) 1.01
A low-molecular-weight heparinoid compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke. A randomized, double-blind study. Ann Intern Med (1992) 1.00
The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: a cross-sectional study. Thromb Haemost (1991) 1.00
The role of D-dimer in the diagnosis of venous thromboembolism. Curr Opin Pulm Med (1997) 0.99
Multiple daily doses of acetyl-salicylic acid (ASA) overcome reduced platelet response to once-daily ASA after coronary artery bypass graft surgery: a pilot randomized controlled trial. J Thromb Haemost (2015) 0.99
MOS HIP: McMaster outcome study of hypertension in pregnancy. Early Hum Dev (2001) 0.99
A latex D-dimer reliably excludes venous thromboembolism. Arch Intern Med (2001) 0.97
Suspected pulmonary embolism in pregnancy: clinical presentation, results of lung scanning, and subsequent maternal and pediatric outcomes. Arch Intern Med (2002) 0.97
Decrease in sensitivity of D-dimer for acute venous thromboembolism after starting anticoagulant therapy. Blood Coagul Fibrinolysis (2002) 0.97
Hodgkin's Disease 1985. Can Fam Physician (1985) 0.96
Comparison of the Villalta and Ginsberg clinical scales to diagnose the post-thrombotic syndrome: correlation with patient-reported disease burden and venous valvular reflux. J Thromb Haemost (2006) 0.94
Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of Clot in This Pregnancy Study Group. N Engl J Med (2000) 0.94
Does the type of hormone replacement therapy influence the risk of deep vein thrombosis? A prospective case-control study. J Thromb Haemost (2005) 0.94
Relation of factor V Leiden genotype to risk for acute deep venous thrombosis after joint replacement surgery. Ann Intern Med (1998) 0.93
D-dimer testing in pregnant patients: towards determining the next 'level' in the diagnosis of deep vein thrombosis. J Thromb Haemost (2010) 0.93
The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: a multi-institutional cohort study of patients who underwent hip or knee arthroplasty. Canadian Collaborative Group. Arch Intern Med (1998) 0.93
Uses of heparin. Ancrod for heparin induced thrombocytopenia. BMJ (1993) 0.92
Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. J Thromb Haemost (2003) 0.92
Effect of warfarin on activated partial thromboplastin time in patients receiving heparin. Arch Intern Med (1998) 0.92
The effects of long-term heparin therapy during pregnancy on bone density. A prospective matched cohort study. Thromb Haemost (1996) 0.90
The clinical utility of a rapid bedside D-dimer assay for screening of deep vein thrombosis following orthopaedic surgery. Thromb Haemost (1997) 0.90
Diagnostic strategies for the management of patients with clinically suspected deep-vein thrombosis. Curr Opin Pulm Med (1997) 0.89
Criteria for evaluating evidence that laboratory abnormalities are associated with the development of venous thromboembolism. CMAJ (2000) 0.88
Tissue plasminogen activator (rt-PA) vs heparin in deep vein thrombosis. Results of a randomized trial. Chest (1990) 0.88
Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. Arch Intern Med (2001) 0.88
Assessing the teratogenic potential of angiotensin-converting enzyme inhibitors in pregnancy. Aust N Z J Obstet Gynaecol (1998) 0.87
Clinical utility of a rapid whole-blood D-dimer assay in patients with cancer who present with suspected acute deep venous thrombosis. Ann Intern Med (1999) 0.87
A reevaluation of the risk for venous thromboembolism with the use of oral contraceptives and hormone replacement therapy. Arch Intern Med (1997) 0.86
The relationship between unprovoked venous thromboembolism, age, and acute myocardial infarction. J Thromb Haemost (2008) 0.86
Low molecular weight heparins (LMWH) in the treatment of patients with acute venous thromboembolism. Thromb Haemost (1995) 0.84
Differences in clinical presentation of deep vein thrombosis in men and women. J Thromb Haemost (2008) 0.84
Use of anticoagulants during pregnancy. Chest (1989) 0.84
Optimal dosing of subcutaneous unfractionated heparin for the treatment of deep vein thrombosis. Thromb Res (2000) 0.83
A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement. J Thromb Haemost (2007) 0.83
Measurement of markers of activated coagulation in antithrombin III deficient subjects. Thromb Haemost (1992) 0.82
Frequency and predictive value of antisperm antibodies among infertile couples. Hum Reprod (1993) 0.82
"Picking winners": assessing new health technology. Med J Aust (1999) 0.81
Relation between D-dimer level, venous valvular reflux and the development of post-thrombotic syndrome after deep vein thrombosis. J Thromb Haemost (2010) 0.81
The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin. Arch Intern Med (1996) 0.81
Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents. J Thromb Haemost (2014) 0.81
Recurrent venous thrombosis and heparin therapy: an evaluation of the importance of early activated partial thromboplastin times. Arch Intern Med (1999) 0.81
Use of different D-dimer levels to exclude venous thromboembolism depending on clinical pretest probability. J Thromb Haemost (2004) 0.80
Low-molecular-weight heparinoid orgaran is more effective than aspirin in the prevention of venous thromboembolism after surgery for hip fracture. Circulation (1996) 0.80
Use of antithrombotic agents during pregnancy. Chest (1995) 0.80
Deep venous thrombosis and pulmonary embolism in pregnancy. Clin Chest Med (1992) 0.79
Bleeding risk and reproductive capacity among patients with factor XIII deficiency: a case presentation and review of the literature. Obstet Gynecol Surv (2000) 0.79
Anticoagulants in pregnancy: fetal effects. Baillieres Clin Obstet Gynaecol (1997) 0.79
The effects of hormone replacement therapy on thrombin generation, fibrinolysis inhibition, and resistance to activated protein C: prospective cohort study and review of literature. Thromb Res (2000) 0.79
The APTT response of pregnant plasma to unfractionated heparin. Thromb Haemost (2002) 0.78
The effects of low-intensity warfarin on coagulation activation in patients with antiphospholipid antibodies and systemic lupus erythematosus. Thromb Haemost (1999) 0.78
Occupation and the follow-up of infertile couples. Fertil Steril (1993) 0.78
Evaluation of the combination of a bedside D-dimer assay and enzyme-linked immunosorbent soluble fibrin assay in patients with suspected venous thromboembolism. Thromb Res (1997) 0.78
Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin. Arch Intern Med (2001) 0.78
Free protein S deficiency may be found in patients with antiphospholipid antibodies who do not have systemic lupus erythematosus. Thromb Haemost (1996) 0.77
First detection of Chlamydia psittaci from a wild native passerine bird in New Zealand. N Z Vet J (2012) 0.77
Use of antithrombotic agents during pregnancy. Chest (1992) 0.77